Clinical Trial

Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 6, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to investigate the efficacy and safety of low-dose radiation combined with neoadjuvant chemotherapy and immunotherapy in the treatment of locally advanced thoracic esophageal squamous cell carcinoma. By reducing the radiation dose from 40 Gy in 20 fractions to 4 Gy in 2 fractions, the goal is to lessen the adverse reactions caused by radiotherapy. Additionally, the study explores whether low-dose radiation therapy can promote the cross-presentation of tumor-specific antigens and increase lymphocyte infiltration into the tumor site. Study also examines whether this approach can enhance tumor-specific immune responses, thereby potentially improving the efficacy of immune checkpoint inhibitors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-04; most recent amendment 2025-06-05.
Status change: Not Yet Recruiting → Recruiting 2025-02-10
Trial Details
NCT Number NCT06446726
Lead Sponsor Sichuan University
Conditions Esophageal Squamous Cell Carcinoma
Enrollment 30 participants
Start Date 2024-06-30
Primary Completion 2025-06-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-06